Pregnancy prescribing in psychiatry is one of the more anxious clinical territories — for patients, families, and prescribers. The framing that matters most is this: untreated psychiatric illness in pregnancy is not safe. Untreated depression is associated with preeclampsia, preterm birth, low birth weight, neonatal outcomes, and postpartum complications. Untreated bipolar disorder carries substantial maternal and fetal risk. The question is not whether to treat, but what to treat with — risk of medication exposure versus risk of untreated illness.
- Class
- Pregnancy/lactation pharmacotherapy framework
- Mechanism
- Risk-benefit framework integrating teratogenicity, neonatal effects, breast milk transfer, maternal illness severity
- FDA indications
- Pregnancy planning, pregnancy management, lactation across psychiatric disorders
- Key adverse effects
- Differs by agent and trimester
Key principle: untreated psychiatric illness in pregnancy has substantial risks (preeclampsia, preterm birth, neonatal outcomes, postpartum complications). The question is not "can we avoid all medication" but "what is the safest effective treatment." Generally preferred: sertraline (SSRI), lamotrigine (mood stabilizer), atypical antipsychotics (haloperidol, olanzapine if needed). Generally avoided: valproate (teratogenic), paroxetine (cardiac), benzodiazepines first trimester.
Generally preferred agents: Sertraline has the most extensive safety data among SSRIs for both pregnancy and lactation; for the patient who needs SSRI treatment, sertraline is usually the choice. Lamotrigine has reasonable pregnancy data for bipolar maintenance, though dose adjustment is often needed because pregnancy alters clearance. Older antipsychotics with extensive data (haloperidol) and selected atypicals (olanzapine has substantial registry data, though with metabolic considerations) when antipsychotic treatment is required. Lithium can be used with careful monitoring — small Ebstein's anomaly risk requires fetal echocardiogram, and pregnancy changes volume of distribution requiring level monitoring.
Generally avoided: Valproate is among the most teratogenic psychiatric medications — neural tube defects, cognitive impairment in offspring, fetal valproate syndrome. FDA pregnancy category X for the bipolar indication. Avoid in women of childbearing potential when alternatives exist. Paroxetine has a cardiac malformation signal; sertraline is preferred when SSRI is needed. Benzodiazepines have first-trimester cleft palate signal and third-trimester floppy baby syndrome — avoid when possible, especially first trimester.
Pregnancy and lactation prescribing is a mechanism-aware balancing act — weighing the drug's pharmacology against fetal/infant exposure and the real risks of untreated maternal illness.
Mechanism note: Perinatal prescribing weighs drug pharmacology against fetal/infant exposure AND against the genuine harms of untreated illness — valproate is the clearest 'avoid', sertraline a frequent 'preferred'.
Postpartum is the highest-risk period for relapse, particularly in bipolar disorder. Plan postpartum monitoring at the start of pregnancy treatment, not after delivery. Brexanolone and zuranolone are now FDA-approved for postpartum depression specifically — important new options for an often-undertreated condition.
Engage the patient in shared decision-making. Coordinate with OB. Document the discussion. The right choice is the one made jointly between patient and clinician with eyes open to both medication and illness risks.